# PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

> **NCT06013371** · PHASE2 · TERMINATED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 32 (actual)

## Conditions studied

- Seborrheic Dermatitis
- Papulopustular Rosacea

## Interventions

- **DRUG:** PF-07038124
- **DRUG:** Placebo Ointment

## Key facts

- **NCT ID:** NCT06013371
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-07-19
- **Primary completion:** 2025-02-18
- **Final completion:** 2025-02-18
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** The study ended early because interim analysis showed no significant difference between the active and placebo arms.
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06013371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06013371, "PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06013371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*